Gala­pa­gos spot­lights an 'ex­cit­ing' round of PoC da­ta for IPF drug, shares surge

Gala­pa­gos $GLPG says it got the proof-of-con­cept da­ta re­searchers were look­ing for from their mid-stage tri­al of GLPG1690 for id­io­path­ic pul­monary fi­bro­sis and will now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER